Alpha-1 Antitrypsin (human) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 231 | Alpha-1-antitrypsin deficiency | 1 |
231. Alpha-1-antitrypsin deficiency
Clinical trials : 93 / Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01669421 (ClinicalTrials.gov) | July 2012 | 14/8/2012 | Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation. | Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency. | Alpha 1 Antitrypsin Deficiency | Drug: Alpha-1 Antitrypsin (human) | Michael Campos, MD | CSL Behring | Completed | 18 Years | 75 Years | All | 10 | Phase 2 | United States |